The pharmaceutical and biotechnology industries have extremely high requirements for product purity and safety. In the processes of drug synthesis and the preparation of biological products (vaccines, proteins, antibiotics), it is necessary to remove impurities from raw materials (such as heavy metals, residual solvents, and byproducts) and separate and purify the target product to ensure drug efficacy and patient safety. Traditional separation and purification processes (such as distillation and filtration) suffer from low efficiency, insufficient purity, and high risk of contamination. Ion exchange resins, with their high selectivity and mild separation conditions, have become the core purification material in this industry.

1. After drug purification, the impurity content is ≤0.1%, and the heavy metal residue is lower than the pharmacopoeia limit (e.g., lead ≤0.001%), resulting in a significant improvement in product purity and efficacy.

2. Biological products (such as proteins and vaccines) retain more than 95% of their activity, solving the problem of denaturation and inactivation caused by traditional processes;

3. The separation and purification steps are simplified by 30%, production efficiency is increased by 40%, and the unit product production cost is reduced by 25-30%.

4. The production process complies with GMP standards, and the products have passed quality inspection and certification, significantly enhancing their market competitiveness.